Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier BV in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (2), 81.e9-81.e16
- https://doi.org/10.1016/j.urolonc.2017.10.018
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetateCancer Chemotherapy and Pharmacology, 2017
- Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover StudiesClinical Pharmacokinetics, 2017
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone DrivenJournal of Clinical Oncology, 2008
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate CancerCancer Research, 2008
- EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATEAnnals of Surgery, 1942